Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance

• Published in: Breast cancer (Tokyo, Japan) Vol. 29; no. 6; pp. 1076 - 1087
• Main Authors: Zhu, Jing, Wu, Wenwen, Togashi, Yukiko, Taira Nihira, Naoe, Johmura, Yoshikazu, Zhu, Dajiang, Nakanishi, Makoto, Miyoshi, Yasuo, Ohta, Tomohiko
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.11.2022; Springer
• Subjects: Breast cancer; Cancer cells; Cancer Research; Health aspects; Medicine; Medicine & Public Health; Metabolites; Oncology; Original; Original Article; Surgery; Surgical Oncology; Tamoxifen; TFEB; Sacituzumab govitecan; Tamoxifen; Trop-2

Background Sacituzumab govitecan is an antibody–drug conjugate that delivers SN-38, an active metabolite of irinotecan, to the target molecule, trophoblast cell-surface antigen 2 (Trop-2). It is a promising drug for triple-negative breast cancer and is anticipated to be effective for luminal breast...